Hans-Peter Grobbel1,2,3, Matthias Merker2,4, Niklas Köhler1,2,3, Sönke Andres5, Harald Hoffmann6,7, Jan Heyckendorf1,2,3, Maja Reimann1,2,3, Ivan Barilar4, Viola Dreyer4, Doris Hillemann5, Barbara Kalsdorf1,2,3, Thomas A Kohl4, Patricia Sanchez Carballo1,2,3, Dagmar Schaub1,2,3, Katharina Todt6,7, Christian Utpatel4, Florian P Maurer5,8, Christoph Lange1,2,3,9, Stefan Niemann2,4,5. 1. Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany. 2. German Center for Infection Research, Clinical Tuberculosis Unit, Borstel, Germany. 3. Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany. 4. Molecular and Experimental Mycobacteriology, National Reference Center for Mycobacteria, Research Center Borstel, Borstel, Germany. 5. National and World Health Organization Supranational Reference Laboratory for Tuberculosis, Research Center Borstel, Borstel, Germany. 6. Institute of Microbiology and Laboratory Medicine, World Health Organization Supranational Reference Laboratory of Tuberculosis, IML red GmbH, Gauting, Bavaria, Germany. 7. SYNLAB Gauting, SYNLAB MVZ of Human Genetics Munich, Bavaria, Germany. 8. Institute for Medical Microbiology, Virology and Hygiene, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 9. Global Tuberculosis Program, Baylor College of Medicine, Houston, Texas, USA.
Abstract
BACKGROUND: Comprehensive and reliable drug susceptibility testing (DST) is urgently needed to provide adequate treatment regimens for patients with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). We determined whether next-generation sequencing (NGS) analysis of Mycobacterium tuberculosis complex isolates and genes implicated in drug resistance can guide the design of effective MDR/RR-TB treatment regimens. METHODS: NGS-based genomic DST predictions of M. tuberculosis complex isolates from MDR/RR-TB patients admitted to a TB reference center in Germany between 1 January 2015 and 30 April 2019 were compared with phenotypic DST results of mycobacteria growth indicator tubes (MGIT). Standardized treatment algorithms were applied to design individualized therapies based on either genomic or phenotypic DST results, and discrepancies were further evaluated by determination of minimal inhibitory drug concentrations (MICs) using Sensititre MYCOTBI and UKMYC microtiter plates. RESULTS: In 70 patients with MDR/RR-TB, agreement among 1048 pairwise comparisons of genomic and phenotypic DST was 86.3%; 76 (7.2%) results were discordant, and 68 (6.5%) could not be evaluated due to the presence of polymorphisms with yet unknown implications for drug resistance. Importantly, 549 of 561 (97.9%) predictions of drug susceptibility were phenotypically confirmed in MGIT, and 27 of 64 (42.2%) false-positive results were linked to previously described mutations mediating a low or moderate MIC increase. Virtually all drugs (99.0%) used in combination therapies that were inferred from genomic DST were confirmed to be susceptible by phenotypic DST. CONCLUSIONS: NGS-based genomic DST can reliably guide the design of effective MDR/RR-TB treatment regimens.
BACKGROUND: Comprehensive and reliable drug susceptibility testing (DST) is urgently needed to provide adequate treatment regimens for patients with multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB). We determined whether next-generation sequencing (NGS) analysis of Mycobacterium tuberculosis complex isolates and genes implicated in drug resistance can guide the design of effective MDR/RR-TB treatment regimens. METHODS: NGS-based genomic DST predictions of M. tuberculosis complex isolates from MDR/RR-TB patients admitted to a TB reference center in Germany between 1 January 2015 and 30 April 2019 were compared with phenotypic DST results of mycobacteria growth indicator tubes (MGIT). Standardized treatment algorithms were applied to design individualized therapies based on either genomic or phenotypic DST results, and discrepancies were further evaluated by determination of minimal inhibitory drug concentrations (MICs) using Sensititre MYCOTBI and UKMYC microtiter plates. RESULTS: In 70 patients with MDR/RR-TB, agreement among 1048 pairwise comparisons of genomic and phenotypic DST was 86.3%; 76 (7.2%) results were discordant, and 68 (6.5%) could not be evaluated due to the presence of polymorphisms with yet unknown implications for drug resistance. Importantly, 549 of 561 (97.9%) predictions of drug susceptibility were phenotypically confirmed in MGIT, and 27 of 64 (42.2%) false-positive results were linked to previously described mutations mediating a low or moderate MIC increase. Virtually all drugs (99.0%) used in combination therapies that were inferred from genomic DST were confirmed to be susceptible by phenotypic DST. CONCLUSIONS: NGS-based genomic DST can reliably guide the design of effective MDR/RR-TB treatment regimens.
Authors: Silke Feuerriegel; Thomas A Kohl; Christian Utpatel; Sönke Andres; Florian P Maurer; Jan Heyckendorf; Agathe Jouet; Nelly Badalato; Lynda Foray; Rashidatu Fouad Kamara; Osman S Conteh; Philip Supply; Stefan Niemann Journal: Eur Respir J Date: 2021-01-05 Impact factor: 16.671
Authors: Sönke Andres; Matthias Merker; Jan Heyckendorf; Barbara Kalsdorf; Rudolf Rumetshofer; Alexander Indra; Sabine Hofmann-Thiel; Harald Hoffmann; Christoph Lange; Stefan Niemann; Florian P Maurer Journal: Am J Respir Crit Care Med Date: 2020-06-15 Impact factor: 21.405
Authors: Christoph Lange; Keertan Dheda; Dumitru Chesov; Anna Maria Mandalakas; Zarir Udwadia; C Robert Horsburgh Journal: Lancet Date: 2019-09-14 Impact factor: 79.321
Authors: Gregory L Armstrong; Duncan R MacCannell; Jill Taylor; Heather A Carleton; Elizabeth B Neuhaus; Richard S Bradbury; James E Posey; Marta Gwinn Journal: N Engl J Med Date: 2019-12-26 Impact factor: 91.245
Authors: Jan Heyckendorf; Sönke Andres; Claudio U Köser; Ioana D Olaru; Thomas Schön; Erik Sturegård; Patrick Beckert; Viola Schleusener; Thomas A Kohl; Doris Hillemann; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Stefan Niemann; Christoph Lange; Matthias Merker Journal: Antimicrob Agents Chemother Date: 2018-01-25 Impact factor: 5.191
Authors: Sebastian M Gygli; Peter M Keller; Matthias Egger; Sebastien Gagneux; Erik C Böttger; Marie Ballif; Nicolas Blöchliger; Rico Hömke; Miriam Reinhard; Chloé Loiseau; Claudia Ritter; Peter Sander; Sonia Borrell; Jimena Collantes Loo; Anchalee Avihingsanon; Joachim Gnokoro; Marcel Yotebieng Journal: Antimicrob Agents Chemother Date: 2019-03-27 Impact factor: 5.191
Authors: Matthias Merker; Thomas A Kohl; Ivan Barilar; Sönke Andres; Philip W Fowler; Erja Chryssanthou; Kristian Ängeby; Pontus Jureen; Danesh Moradigaravand; Julian Parkhill; Sharon J Peacock; Thomas Schön; Florian P Maurer; Timothy Walker; Claudio Köser; Stefan Niemann Journal: Genome Med Date: 2020-03-06 Impact factor: 11.117
Authors: O W Akkerman; R Duarte; S Tiberi; H S Schaaf; C Lange; J W C Alffenaar; J Denholm; A C C Carvalho; M S Bolhuis; S Borisov; J Bruchfeld; A M Cabibbe; J A Caminero; I Carvalho; J Chakaya; R Centis; M P Dalcomo; L D Ambrosio; M Dedicoat; K Dheda; K E Dooley; J Furin; J-M García-García; N A H van Hest; B C de Jong; X Kurhasani; A G Märtson; S Mpagama; M Munoz Torrico; E Nunes; C W M Ong; D J Palmero; R Ruslami; A M I Saktiawati; C Semuto; D R Silva; R Singla; I Solovic; S Srivastava; J E M de Steenwinkel; A Story; M G G Sturkenboom; M Tadolini; Z F Udwadia; A R Verhage; J P Zellweger; G B Migliori Journal: Int J Tuberc Lung Dis Date: 2022-07-01 Impact factor: 3.427
Authors: Peter M Mbelele; Christian Utpatel; Elingarami Sauli; Emmanuel A Mpolya; Beatrice K Mutayoba; Ivan Barilar; Viola Dreyer; Matthias Merker; Margaretha L Sariko; Buliga M Swema; Blandina T Mmbaga; Jean Gratz; Kennedy K Addo; Michel Pletschette; Stefan Niemann; Eric R Houpt; Stellah G Mpagama; Scott K Heysell Journal: JAC Antimicrob Resist Date: 2022-04-21
Authors: Iris Finci; Audrey Albertini; Matthias Merker; Sönke Andres; Nino Bablishvili; Ivan Barilar; Tatiana Cáceres; Valeriu Crudu; Eduardo Gotuzzo; Nchimunya Hapeela; Harald Hoffmann; Christine Hoogland; Thomas A Kohl; Katharina Kranzer; Anna Mantsoki; Florian P Maurer; Mark P Nicol; Ecaterina Noroc; Sara Plesnik; Timothy Rodwell; Morten Ruhwald; Theresa Savidge; Max Salfinger; Elizabeth Streicher; Nestani Tukvadze; Robin Warren; Widaad Zemanay; Anna Zurek; Stefan Niemann; Claudia M Denkinger Journal: Lancet Microbe Date: 2022-07-27